Rheumatoid Arthritis

Diagnosis and Tests for Rheumatoid Arthritis

Whether you’re well-versed in the intricacies of autoimmune conditions or are stepping into this domain for the first time, it’s important to know that getting an early diagnosis for rheumatoid arthritis (RA) is essential when it comes to preventing complications. We will be covering the importance of getting an early diagnosis, what role your medical history plays, and the variety of laboratory and imaging tests that are typically done. 

What Is Rheumatoid Arthritis?

Rheumatoid arthritis is a chronic inflammatory disorder that primarily affects the joints, but can also affect other systems of the body, including the heart and lungs. It’s an autoimmune condition, meaning it arises when the immune system mistakenly attacks the body's own tissues. In RA, the attack begins primarily with the synovium — the lining of the membranes that surround the joints. It’s characterized by painful swelling in the affected joints, potentially leading to joint damage and even erosion of the bones. (Source, Source)

Importance of Early Diagnosis and Testing for Rheumatoid Arthritis

The journey through RA often begins with subtle symptoms that may be easy to overlook: a stiffness in the fingers, a persistent ache in the joints, or lingering fatigue. These symptoms may seem minor, but may signal the onset of RA. Early diagnosis and testing are not merely helpful steps; they are pivotal in altering the course of RA, potentially halting its progression and mitigating its impact on your life.

Research indicates that early detection of RA is critical to managing its progression and reducing potential joint damage and related complications. The window of opportunity for optimal management of RA often lies in its early stages, where interventions can significantly affect the course of the disease, preserving joint function, enhancing quality of life, and increasing the likelihood of achieving disease remission. Thus, understanding and recognizing the early signs of RA and seeking timely medical advice is paramount in safeguarding your health and well-being. (Source, Source)

Diagnostic Criteria for Rheumatoid Arthritis

Navigating through the diagnostic pathway for rheumatoid arthritis involves a careful evaluation of various aspects, from clinical signs to laboratory tests. Understanding the criteria health care professionals use to diagnose RA can empower you with knowledge and, perhaps, bring you a feeling of clarity and control amid the complexities of this journey.

Clinical Signs and Symptoms

The initial signs of RA can be subtle and may be easily dismissed. These may include persistent joint pain, swelling, and stiffness, particularly in the smaller joints of the hands and feet. The symmetry of symptoms, where both sides of the body are affected similarly, is also a characteristic feature of RA. Understanding and being able to accurately communicate these symptoms to your health care provider is a crucial step in getting an accurate diagnosis. (Source)

Duration of Symptoms

Looking at the duration of symptoms is important in the diagnostic process. Typically, for a diagnosis of RA symptoms should have been present for at least 6 weeks. This helps distinguish RA from other forms of arthritis and conditions that may present with similar early symptoms. It’s essential to keep a detailed record of your symptoms, noting their onset and progression, to assist your health care team in piecing together the diagnostic puzzle. (Source)

Laboratory and Imaging Studies

Laboratory tests and imaging studies are integral in confirming a diagnosis of RA and understanding its progression. Blood tests, such as those measuring rheumatoid factors (RF) and anti-citrullinated protein antibodies (ACPA), can provide valuable insights into the inflammatory and autoimmune aspects of RA. Imaging studies, including X-rays and ultrasounds, can help visualize joint damage and inflammation that might be occurring, even in the absence of noticeable symptoms. (Source, Source)

Exclusion of Other Conditions

Rheumatoid arthritis can sometimes masquerade as other conditions, and vice versa, due to an overlap of symptoms. Therefore, part of the diagnostic process involves excluding other potential conditions that might mimic RA, such as lupus, Sjögren’s syndrome, or osteoarthritis. This process, known as a differential diagnosis, ensures the diagnosis reached is accurate, and the management plan formulated is targeted and effective. (Source)

Your Medical History: A Vital Chapter in Your Rheumatoid Arthritis Journey

Navigating through the diagnosis of rheumatoid arthritis is a path that intertwines your unique experiences, symptoms, and history. Your medical history is not merely a collection of facts, but a rich narrative that provides health care professionals with insights into your health journey, helping them craft a diagnosis and management plan that’s uniquely tailored to you.

Understanding RA and its impact on your life requires a comprehensive look at your medical history. This holistic approach ensures that your health care provider has a clear picture of your health, so they can offer the most effective care tailored to your unique needs. Let's explore what you can expect during this process, and the types of questions that may arise.

What to Expect

Embarking on a discussion about your medical history might feel like a dive into a sea of questions, but it’s a space where your experiences, symptoms, and familial health patterns help health care professionals understand your health in a holistic manner. 

Your medical history is a crucial component of the diagnostic process and provides invaluable insights into potential risk factors, triggers, and patterns that might be associated with RA. It's important to remember that each piece of information you share contributes to a clearer understanding of your health journey.

General Health and Lifestyle

Your overall health and lifestyle can offer clues about potential triggers or exacerbating factors for RA. Here are some sample questions you might encounter.

  1. How would you describe your overall health in the last year?
  2. Do you have any known allergies or sensitivities?
  3. Are there any specific lifestyle factors, such as smoking or alcohol consumption, that we should be aware of?

Symptoms and Triggers

Understanding the nature, duration, and triggers of your symptoms helps to paint a detailed picture of your RA journey. Some questions might include:

  1. Can you describe the nature and intensity of your joint symptoms?
  2. Have you noticed any specific triggers that seem to worsen your symptoms?
  3. How long have you been experiencing these symptoms, and have they changed over time?

Family History

Your family history provides a glimpse into any genetic predispositions that might be relevant to understanding your symptoms. Questions might encompass:

  1. Do any of your immediate family members have RA, or another autoimmune condition?
  2. Are there any other prevalent health conditions in your family?
  3. Has anyone in your family experienced similar symptoms, even if they were not diagnosed with RA?

Medical Records

Your past medical records can provide a wealth of information, especially regarding previous treatments, surgeries, or diagnoses. Here are some questions to be prepared for:

  1. Have you ever been diagnosed with another autoimmune condition?
  2. Are you currently on any medications, and if so, can you provide a list?
  3. Have you undergone any surgeries or significant medical procedures in the past?

Laboratory Tests in Rheumatoid Arthritis Diagnosis: Unveiling the Invisible

Navigating through the diagnosis of rheumatoid arthritis involves understanding the unseen — the aspects of the condition that are not visible to the naked eye but are crucial in painting a comprehensive picture of your health. Laboratory tests play an important role in this, offering insights into the internal workings of your body and providing key information that aids in confirming a diagnosis of RA.

Rheumatoid Factors: Key Players in RA Diagnosis

Rheumatoid factors (RF) are proteins produced by your immune system that can attack healthy tissues, a characteristic feature of autoimmune diseases like RA.

What Do High Levels of RF Mean? 

Elevated RF levels, while not exclusive to RA, can indicate its presence and suggest a more aggressive disease course. However, it’s crucial to note that RF can be elevated in other inflammatory autoimmune conditions and even in healthy individuals, making them just one piece of the diagnostic puzzle. (Source)

Anti-Citrullinated Protein Antibodies: Specific Markers

Anti-citrullinated protein antibodies (ACPA), also known as anti-cyclic citrullinated peptide antibodies, are other antibodies often tested in RA diagnosis due to their higher specificity, meaning they are better at identifying those without the disease, compared to RF. 

What Do High Levels of ACPA Mean? 

An elevated level of ACPA is strongly associated with RA, and can even precede clinical symptoms. High levels may also be indicative of more severe disease progression. (Source)

Inflammatory Markers: Erythrocyte Sedimentation Rate and C-Reactive Protein

Inflammation is a hallmark of RA, so evaluating inflammatory markers becomes essential. Erythrocyte sedimentation rate and C-reactive protein are two markers that are commonly assessed.

  • erythrocyte sedimentation rate (ESR): Inflammation in the body can cause red blood cells (erythrocytes) to clump together so that when placed in a test tube they fall to the bottom more quickly than normal, an effect known as an increased sedimentation rate. It’s not specific to RA but can signal the need for further investigation. The ESR is often used alongside other tests and clinical findings to confirm a diagnosis. (Source, Source)

  • C-reactive protein (CRP): Levels of CRP, a protein produced in the liver, rise in response to inflammation and can be particularly useful in monitoring disease activity and the effectiveness of treatments. As with ESR, CRP indicates the presence of inflammation in the body but is not specific to RA. (Source, Source)

Complete Blood Count: A Broader Perspective

A complete blood count (CBC) provides a general overview of your health by measuring different cells in your blood, including those that fight infection, help blood to clot, and carry oxygen to all parts of your body. Having a CBC done can help to identify whether you have anemia — a low number of red blood cells — which is commonly seen in those with RA. If you are diagnosed with RA, your CBC will be monitored for signs of disease progression and the effects of some RA treatments, which can cause changes to your white blood cells and platelets. (Source, Source)

Other Blood Tests and Relevant Biomarkers

In addition to RF, ACPA, ESR, and CRP, other biomarkers might be explored to gain further insights into your condition and to rule out other potential causes of your symptoms. These might include:

  • anti-Sa antibodies: These antibodies are more specific to RA than other markers of inflammation such as RF. (Source)
  • anti-MCV antibodies: These can provide additional information, especially in cases where ACPA is not detected. (Source)
  • antinuclear antibodies (ANAs): Antinuclear antibodies attack components of a cell’s nucleus, where genetic material (DNA and RNA) are found. These antibodies are not specific to RA or any other autoimmune disorder, as many healthy people also have them. (Source, Source)

Imaging Studies in RA Diagnosis: Illuminating the Invisible

There is often more than meets the eye when it comes to diagnosing rheumatoid arthritis. Imaging studies play a pivotal role in visualizing the internal structures of your joints, providing invaluable insights that guide health care providers in understanding the intricacies of your condition.

Role of X-Ray Imaging: The First Glimpse

X-ray imaging often serves as the first step in visualizing joint abnormalities associated with RA. It provides a fundamental overview, revealing changes in the joints that might be suggestive of RA, such as the loss of bone due to disease progression, or other abnormalities. While X-ray imaging is instrumental in detecting joint damage, it does not make soft tissues visible and may not capture the early inflammatory changes of RA. It serves as a tool to monitor the progression of the disease, especially in observing the development and progression of joint deformities. (Source)

Ultrasound: A Closer Look

Ultrasound imaging allows health care providers to visualize soft tissues in addition to bone, providing a detailed view of the synovium (the connective tissue that surrounds the joints) and enabling them to identify synovitis (inflammation of the synovium), even in joints that might appear normal during a physical examination. This is important for RA because the presence of synovitis signals that the disease is active. (Source)

Magnetic Resonance Imaging (MRI) for Detailed Assessment: Peering Deeper

MRI offers a detailed and comprehensive view of the joints, capable of visualizing both bone and soft tissue structures, making it a powerful tool in assessing the extent and severity of RA.

MRI can detect synovitis, bone marrow edema (when fluid builds up in the bone marrow), and bone erosions, even in the early stages of RA, providing a detailed assessment that aids in understanding the depth and severity of the condition. Research has found that up to 60% of patients with RA experience bone loss after 1 year. MRI is especially useful in cases where ultrasound and X-ray findings are inconclusive. (Source, Source)

Exploring Further: Other Imaging Techniques

  • positron emission tomography and computed tomography (PET/CT) scans: Used primarily for detecting cancer inside the body, PET/CT scans can also uncover damage to joints caused by RA and can be used both to diagnose and to monitor disease progression. (Source, Source)
  • dual-energy x-ray absorptiometry (DEXA) scans: Rheumatoid arthritis causes loss of bone mineral density and leads to osteoporosis in up to 50% of people with RA. DEXA scans are primarily used to assess bone density and risk of osteoporosis. (Source, Source)

The Bottom Line

Rheumatoid arthritis diagnosis is a multifaceted process, bringing together clinical evaluations, laboratory tests, and imaging studies to paint a comprehensive picture of your health. From evaluating clinical signs and symptoms and exploring your medical history, to delving into laboratory tests such as RF, ACPA, and inflammatory markers, to employing imaging studies such as x-rays and MRIs, each step is crucial in forming a precise diagnosis. Understanding RA and its diagnostic process is a potent tool, enabling you to be an active participant and advocate in managing your health.


Aletaha,, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., III, Birnbaum, N. S., Burmester, G. R., Bykerk, V. P., Cohen, M. D., Combe, B., Costenbader, K. H., Dougados, M., Emery, P., Ferraccioli, G., Hazes, J. M. W., Hobbs, K., Huizinga, T. W. J., Kavanaugh, A.,  . . . Hawker, G. (2010). 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis & Rheumatism, 62(9), 2569–2581. https://doi.org/10.1002/art.27584

Casey, J. (2009). Anti-MCV antibodies—A promising new biomarker for RA. Nature Reviews Rheumatology, 5(4), Article 4. https://doi.org/10.1038/nrrheum.2009.59

Centers for Disease Control and Prevention. (n.d.). Rheumatoid arthritis (RA). U.S. Department of Health and Human Services. https://www.cdc.gov/arthritis/basics/rheumatoid-arthritis.html

Hafez, E. A., Mansour, H. E., Hamza, S. H., Moftah, S. G., Younes, T. B., & Ismail, M. A. (2011). Bone mineral density changes in patients with recent-onset rheumatoid arthritis. Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders, 4, 87–94. https://doi.org/10.4137/CMAMD.S7773

Heidari, B. (2011). Rheumatoid arthritis: Early diagnosis and treatment outcomes. Caspian Journal of Internal Medicine, 2(1), 161–170. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766928/

Hitchon, C. A., & El-Gabalawy, H. S. (2011). The synovium in rheumatoid arthritis. Open Rheumatology Journal, 5, 107–114. https://doi.org/10.2174/1874312901105010107

Hotta, M., Minamimoto, R., Kaneko, H., & Yamashita, H. (2020). Fluorodeoxyglucose PET/CT of arthritis in rheumatic diseases: A pictorial review. RadioGraphics, 40(1), 223–240. https://doi.org/10.1148/rg.2020190047

Iyengar, K. P., Vaish, A., & Nune, A. (2021). Anti-cyclic citrullinated peptide antibody (ACPA) and rheumatoid arthritis: Clinical relevance. Journal of Clinical Orthopaedics and Trauma, 24, 101729. https://doi.org/10.1016/j.jcot.2021.101729

Kgoebane, K., Ally, M. M. T. M., Duim-Beytell, M. C., & Suleman, F. E. (2018). The role of imaging in rheumatoid arthritis. SA Journal of Radiology, 22(1), 1316. https://doi.org/10.4102/sajr.v22i1.1316

Krugh, M., & Langaker, M. D. (2023, June 5). Dual-energy X-ray absorptiometry. StatPearls [Internet]. Retrieved October 17, 2023, from https://www.ncbi.nlm.nih.gov/books/NBK519042/

Liu, J., Gao, J., Wu, Z., Mi, L., Li, N., Wang, Y., Peng, X., Xu, K., Wu, F., & Zhang, L. (2022). Anti-citrullinated protein antibody generation, pathogenesis, clinical application, and prospects. Frontiers in Medicine, 8, 802934. https://doi.org/10.3389/fmed.2021.802934

MedlinePlus. (2022, September 28). C-reactive protein (CRP) test. National Institutes of Health, National Library of Medicine. https://medlineplus.gov/lab-tests/c-reactive-protein-crp-test/

MedlinePlus. (2022, November 8). Erythrocyte sedimentation rate (ESR). National Institutes of Health, National Library of Medicine. https://medlineplus.gov/lab-tests/erythrocyte-sedimentation-rate-esr/

Nell, V. P. K., Machold, K. P., Eberl, G., Stamm, T. A., Uffmann, M., & Smolen, J. S. (2004). Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology, 43(7), 906–914. https://doi.org/10.1093/rheumatology/keh199

Nosal, R. S., Superville, S. S., Amraei, R., & Varacallo, M. (2022, December 29). Biochemistry, antinuclear antibodies (ANA). StatPearls [Internet]. Retrieved October 17, 2023, from https://www.ncbi.nlm.nih.gov/books/NBK537071/

Paknikar, S. S., Crowson, C. S., Davis, J. M., & Thanarajasingam, U. (2021). Exploring the role of antinuclear antibody positivity in the diagnosis, treatment, and health outcomes of patients with rheumatoid arthritis. ACR Open Rheumatology, 3(6), 422–426. https://doi.org/10.1002/acr2.11271

Panagopoulos, P. K., & Lambrou, G. I. (2018). Bone erosions in rheumatoid arthritis: Recent developments in pathogenesis and therapeutic implications. Journal of Musculoskeletal & Neuronal Interactions, 18(3), 304–319. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146189/

Pope, J. E., & Choy, E. H. (2021). C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Seminars in Arthritis and Rheumatism, 51(1), 219–229. https://doi.org/10.1016/j.semarthrit.2020.11.005

Smith, M. A., Knight, S. M., Maddison, P. J., & Smith, J. G. (1992). Anaemia of chronic disease in rheumatoid arthritis: Effect of the blunted response to erythropoietin and of interleukin 1 production by marrow macrophages. Annals of the Rheumatic Diseases, 51(6), 753–757. https://doi.org/10.1136/ard.51.6.753

Suresh, E. (2004). Diagnosis of early rheumatoid arthritis: What the non-specialist needs to know. Journal of the Royal Society of Medicine, 97(9), 421–424. https://doi.org/10.1177/014107680409700903

Taylor, P. C. (2020). Update on the diagnosis and management of early rheumatoid arthritis. Clinical Medicine, 20(6), 561–564. https://doi.org/10.7861/clinmed.2020-0727

Tiwari, V., Jandu, J. S., & Bergman, M. J. (2023). Rheumatoid factor. StatPearls [Internet]. Retrieved October 13, 2023, from http://www.ncbi.nlm.nih.gov/books/NBK532898/

Vossenaar, E. R., Després, N., Lapointe, E., van der Heijden, A., Lora, M., Senshu, T., van Venrooij, W. J., & Ménard, H. A. (2004). Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Research & Therapy, 6(2), R142-150. https://doi.org/10.1186/ar1149

Yamashita, H., Kubota, K., & Mimori, A. (2014). Clinical value of whole-body PET/CT in patients with active rheumatic diseases. Arthritis Research & Therapy, 16(5), 423. https://doi.org/10.1186/s13075-014-0423-2